AT-101 | 1308272-13-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃类
• 英文名称: AT-101
• 英文别名: (3R,3aR,6S,6aR)-6-methylhexahydrofuro[3,2-b]furan-3-ol；(3S,3aR,6R,6aR)-3-methyl-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-ol
• CAS: 1308272-13-0
• 化学式: C₇H₁₂O₃
• 分子量: 144.17
• InChiKey: JUHJMRCPZRWQAM-BDVNFPICSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  tert-butyldimethyl ((3R,3aS,6aR)-6-methylenehexahydrofuro[3.2-b]furan-3-yloxy)silane 在 palladium on activated charcoal 氢气 、 四丁基氟化铵 作用下， 以 乙酸乙酯 、 四氢呋喃 为溶剂， 反应 2.08h， 生成 (3R,3aR,6R,6aR)-6-methylhexahydrofuro[3,2-b]furan-3-ol 、 AT-101
  参考文献：
  名称：

  [EN] TETRAHYDROFURO (3, 2 -B) PYRROL- 3 -ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES
  [FR] COMPOSÉS

  摘要：

  公开号：

  WO2009087379A3

文献信息

• Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
  申请人：deLong A. Mitchell

  公开号：US20070254920A1

  公开（公告）日：2007-11-01

  This invention relates to novel homotopic prodrugs and medicaments and methods for their preparation, testing and use. In one embodiment, the homotopic prodrug has the general formula wherein is a biologically-active moiety comprising a carboxylic acid functional group, and R b is a homotopically-symmetrical alcohol bonded to the biologically-active moiety through the carboxylic acid functional group to form an ester linkage, as well as optical isomers, enantiomers, pharmaceutically acceptable salts, biohydrolyzable amides, esters, and imides thereof and combinations thereof.

  这项发明涉及新型同位素前药、药物以及其制备、测试和使用方法。在一个实施例中，同位素前药具有一般公式 其中 是包含羧酸官能团的生物活性基团，而 R b 是通过羧酸官能团与生物活性基团形成酯键的同位对称醇，以及其光学异构体、对映异构体、药用可接受盐、生物水解酰胺、酯、亚酰胺及其组合物。
• [EN] TETRAHYDROFURO [3, 2-B] PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEASES<br/>[FR] DÉRIVÉS DE TÉTRAHYDROFURO[3,2-B]PYRROL-3-ONE COMME INHIBITEURS DE CYSTÉINE PROTÉASES
  申请人：AMURA THERAPEUTICS LTD

  公开号：WO2009144450A1

  公开（公告）日：2009-12-03

  A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, wherein one of R1 and R2 is H, and the other is selected fromC1-8-alkyl, C3-6-cycloalkyl and C1-8-alkyl-C5-10-aryl; R3 is selected from tert-butyl, cyclopentyl and 1-methylcyclopentyl; R9 is selected from the following: (F). The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of various diseases.

  一种具有式（I）的化合物，或其药学上可接受的盐、水合物、络合物或前药，其中R1和R2中的一个是H，另一个选自C1-8-烷基、C3-6-环烷基和C1-8-烷基-C5-10-芳基；R3选自叔丁基、环戊基和1-甲基环戊基；R9选自以下内容：（F）。本发明还涉及包括式（I）化合物的药物组合物，以及利用这些化合物治疗各种疾病。
• INDANE BISPHENOLS, POLYMERS DERIVED THEREFROM, AND METHODS OF USE THEREOF
  申请人：Schultz Hume Laura G.

  公开号：US20140061533A1

  公开（公告）日：2014-03-06

  Disclosed herein are indane bisphenol monomer units, and polymers derived from such monomer units. Also disclosed herein are blends including such polymers, articles made from such polymers and blends, methods of using such monomers, polymers, and blends, and processes for preparing such monomers, polymers, and blends.

  本发明涉及indane双酚单体单元以及由此类单体单元衍生的聚合物。本发明还涉及包括此类聚合物的混合物，由此类聚合物和混合物制成的物品，使用此类单体、聚合物和混合物的方法，以及制备此类单体、聚合物和混合物的工艺。
• BISPHENOL POLYMER STRUCTURAL UNITS AND METHOD OF MAKING THE SAME
  申请人：Swaminathan Shubashree

  公开号：US20120149923A1

  公开（公告）日：2012-06-14

  Provided herein are isosorbide-based bisphenol polymer structural units and methods of making the same. These structural units may be polymerized with one or more other types of structural units to form polymers, such as polycarbonates.

  本文提供了基于异山梨醇的双酚聚合物结构单元及其制备方法。这些结构单元可以与一种或多种其他类型的结构单元聚合形成聚合物，如聚碳酸酯。
• DHA Esters and Use Thereof In Treatment and Prevention of Cardiovascular Disease
  申请人：Brune Frédérique

  公开号：US20090312354A1

  公开（公告）日：2009-12-17

  The present invention relates to a docosahexaenoic acid ester with an alcohol chosen among the group-B vitamins or provitamins, advantageously comprised by: nicotinyl alcohol of the following formula (I), panthenol of the following formula (II), and inositol of the following formula (III) or with isosorbide of the following formula (IV) or isosorbide mononitrate of the following formula (V). It also relates to a method of preparation of same, a pharmaceutical composition comprising same and the use of same in the treatment or prevention of cardiovascular disease, in particular auricular fibrillation.

  本发明涉及一种具有从B族维生素或前维生素中选择的醇的十二碳六烯酸酯，优选包括以下公式（I）的烟酰醇，以下公式（II）的泛醇，以下公式（III）的肌醇或以下公式（IV）的异山梨醇或以下公式（V）的单硝酸异山梨醇。本发明还涉及一种制备方法，一种包含该酯的药物组合物以及在治疗或预防心血管疾病，特别是心房颤动方面的应用。